Patent · US Active

Use of cannabinoids in the treatment of epilepsy

US11357741B2 · kind B2 · utility

26Cited by
38References
28Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 4, 2020
Grant dateJun 14, 2022
Priority date—
Expiry dateAug 18, 2040

Classification

  • Technology area (CPC B)Performing Operations; Transporting
  • CPC primaryB01D11/0288
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.